These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 11858908

  • 1. In vitro activity of clinafloxacin in comparison with other quinolones against Stenotrophomonas maltophilia clinical isolates in the presence and absence of reserpine.
    Ribera A, Jurado A, Ruiz J, Marco F, Del Valle O, Mensa J, Chaves J, Hernández G, Jiménez de Anta MT, Vila J.
    Diagn Microbiol Infect Dis; 2002 Feb; 42(2):123-8. PubMed ID: 11858908
    [Abstract] [Full Text] [Related]

  • 2. Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposure.
    Peterson ML, Hovde LB, Wright DH, Hoang AD, Raddatz JK, Boysen PJ, Rotschafer JC.
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2251-5. PubMed ID: 10471574
    [Abstract] [Full Text] [Related]

  • 3. Activity of clinafloxacin, compared with six other quinolones, against Acinetobacter baumannii clinical isolates.
    Vila J, Ribera A, Marco F, Ruiz J, Mensa J, Chaves J, Hernandez G, Jimenez De Anta MT.
    J Antimicrob Chemother; 2002 Mar; 49(3):471-7. PubMed ID: 11864947
    [Abstract] [Full Text] [Related]

  • 4. Comparative in vitro activity of quinolones against Stenotrophomonas maltophilia.
    Valdezate S, Vindel A, Baquero F, Cantón R.
    Eur J Clin Microbiol Infect Dis; 1999 Dec; 18(12):908-11. PubMed ID: 10691206
    [Abstract] [Full Text] [Related]

  • 5. Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods.
    Visalli MA, Bajaksouzian S, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 1997 Jul; 41(7):1475-81. PubMed ID: 9210669
    [Abstract] [Full Text] [Related]

  • 6. In vitro activity of eight fluoroquinolones against multiresistant Stenotrophomonas maltophilia.
    Sánchez-Hernández J, Manzanares MA, Gutiérrez Zufiaurre MN, Muñoz Criado S, Muñoz Bellido JL, García-Rodríguez JA.
    Rev Esp Quimioter; 1999 Sep; 12(3):234-6. PubMed ID: 10878514
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae.
    Nagai K, Davies TA, Pankuch GA, Dewasse BE, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2740-6. PubMed ID: 10991854
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia.
    Zhang L, Li XZ, Poole K.
    J Antimicrob Chemother; 2001 Oct; 48(4):549-52. PubMed ID: 11581236
    [Abstract] [Full Text] [Related]

  • 14. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
    Rolston KV, Ho DH, LeBlanc B, Streeter H, Dvorak T.
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():15-22. PubMed ID: 9222065
    [Abstract] [Full Text] [Related]

  • 15. Activities of 13 quinolones by three susceptibility testing methods against a collection of Haemophilus influenzae isolates with different levels of susceptibility to ciprofloxacin: evidence for cross-resistance.
    Pérez-Vázquez M, Román F, Varela MC, Cantón R, Campos J.
    J Antimicrob Chemother; 2003 Jan; 51(1):147-51. PubMed ID: 12493800
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
    Bauernfeind A.
    J Antimicrob Chemother; 1997 Nov; 40(5):639-51. PubMed ID: 9421311
    [Abstract] [Full Text] [Related]

  • 17. Antimicrobial susceptibility profile of contemporary clinical strains of Stenotrophomonas maltophilia isolates: can moxifloxacin activity be predicted by levofloxacin MIC results?
    Galles AC, Jones RN, Sader HS.
    J Chemother; 2008 Feb; 20(1):38-42. PubMed ID: 18343741
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Antimicrobial susceptibility profile of molecular typed cystic fibrosis Stenotrophomonas maltophilia isolates and differences with noncystic fibrosis isolates.
    Cantón R, Valdezate S, Vindel A, Sánchez Del Saz B, Maíz L, Baquero F.
    Pediatr Pulmonol; 2003 Feb; 35(2):99-107. PubMed ID: 12526070
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.